A Phase Ib Study of TQB2450 Combined With Anlotinib in Patients With Limited Stage Small Cell Lung Cancer After First-line Radiotherapy and Chemotherapy

NCT05942508 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Limited Stage Small Cell Lung Cancer
Not Progressed After First-line Chemoradiotherapy

Interventions

DRUG: TQB2450 Injection + Anlotinib Hydrochloride Capsules

Sponsor

Jinming Yu